Dossier
US regulatory review
Coverage of US regulatory review in the Nexus archive.
- AstraZeneca could be Britain’s next loss
AstraZeneca's potential merger with Bristol Myers Squibb could shift more of its revenue away from the UK and Europe, possibly leading to a New York relisting. US regulatory demands might require commitments to US research, manufacturing, and employment, further distancing the company from the UK. Recent trends show UK-based firms increasingly relisting in New York or being acquired by US rivals.